Guardant Health, Inc. (NASDAQ:GH) Stake Cut by Oak Ridge Investments LLC

Oak Ridge Investments LLC decreased its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 7.9% in the 4th quarter, Holdings Channel reports. The firm owned 14,331 shares of the company’s stock after selling 1,221 shares during the quarter. Oak Ridge Investments LLC’s holdings in Guardant Health were worth $438,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of the business. JNBA Financial Advisors acquired a new stake in Guardant Health in the third quarter worth $26,000. Ashton Thomas Securities LLC bought a new position in shares of Guardant Health during the third quarter worth about $34,000. Quarry LP acquired a new stake in shares of Guardant Health in the 2nd quarter worth about $44,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Guardant Health in the 2nd quarter valued at about $71,000. Finally, Nisa Investment Advisors LLC boosted its stake in Guardant Health by 168.1% during the 3rd quarter. Nisa Investment Advisors LLC now owns 3,434 shares of the company’s stock valued at $79,000 after purchasing an additional 2,153 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Guardant Health

In other news, Director Meghan V. Joyce sold 2,896 shares of the business’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total transaction of $86,590.40. Following the transaction, the director now directly owns 7,648 shares in the company, valued at $228,675.20. The trade was a 27.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Musa Tariq sold 2,320 shares of the stock in a transaction on Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the sale, the director now owns 2,676 shares of the company’s stock, valued at approximately $93,660. This represents a 46.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 5,432 shares of company stock valued at $175,423 over the last quarter. Company insiders own 5.50% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on GH shares. Leerink Partners dropped their price target on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. JPMorgan Chase & Co. boosted their price target on Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. The Goldman Sachs Group raised their price target on Guardant Health from $32.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, Sanford C. Bernstein reduced their price objective on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, October 30th. Fifteen analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $40.60.

Guardant Health Stock Performance

Shares of NASDAQ:GH opened at $36.66 on Monday. The company has a market capitalization of $4.53 billion, a PE ratio of -8.65 and a beta of 1.28. The stock has a fifty day moving average of $33.76 and a 200-day moving average of $28.96. Guardant Health, Inc. has a one year low of $15.81 and a one year high of $39.29.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). The firm had revenue of $191.48 million for the quarter, compared to analysts’ expectations of $170.49 million. Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. Guardant Health’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.73) earnings per share. As a group, research analysts forecast that Guardant Health, Inc. will post -3.44 EPS for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.